Lineage Cell Therapeutics Q4 2022 Earnings Report

Lineage Cell Therapeutics EPS Results

• Actual EPS: -$0.03
• Consensus EPS: -$0.03
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Lineage Cell Therapeutics Revenue Results

• Actual Revenue: $1.92 million
• Expected Revenue: $2.97 million
• Beat/Miss: Missed by -$1.05 million
• YoY Revenue Growth: N/A

Lineage Cell Therapeutics Announcement Details

• Quarter: Q4 2022
• Date: 3/9/2023
• Time: N/A

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX), a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.